Phase 1 N=20 Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
HCV Infection
Primary: Pharmacokinetic (PK) Parameter of Voxilaprevir: AUClast — 662.7; 383.3 h*ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=99 A Study Comparing User Experience of Different Delivery Devices for Glucagon
Healthy
Primary: Percentage of Trained Users That Performed a Successful Administration for Each Device — 90.3; 15.6 percentage of participants — p=<.0001
Phase 1 N=32 Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Drug Interaction Potential
Primary: Pharmacokinetic Analysis: Maximum Concentration (Cmax) for Midazolam — 13.6; 12.0; 9.7 ng/mL
Phase 1 N=16 Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)
HIV Infections
Primary: Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing (AUC[0 to Tau]) of Dolutegravir for Dolutegravir Arm — 64627.8 Hours*…
Phase 1 N=33 Study Evaluating ECG Effects, Safety, Tolerability and Pharmacokinetics of Single Doses of Modufolin (Arfolitixorin) in Healthy Volunteers Tetrahydrofolate in Healthy Male Volunteers
Phase I Study in Healthy Volunteers to Evaluate ECG Effect
Primary: Change-from-baseline QTcF (ΔQTcF) — 2.8; 9.2; 8.5; 1.1 msec
Phase 1 N=122 A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules
Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Dexlansoprazole — 610.1; 622.5; 1381; 1302 nanogram/milliliter (ng/mL)
Phase 1 N=24 Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers
Aspergillus Infections · Candida Infections · Fungal Infections
Primary: Cmax of Voriconazole — 2433.7; 1997.0 ng/mL
Phase 1 N=189 A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
Lymphoma, Non-Hodgkin · Lymphoma, Follicular · Lymphoma, Large B-Cell, Diffuse
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) in First 2 Cycles of Portion A — 0; 0; 0; 0 Participants
Phase 1 N=65 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
Carcinoma, Midline
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)-Part 1 QD — 3; 4; 1; 3 Participants
Phase 1 N=48 2-Week Study In People With Nonalcoholic Fatty Liver Disease
Non-alcoholic Steatohepatitis · Non-alcoholic Fatty Liver Disease
Primary: Relative Change From Baseline in Whole Liver Fat at Day 15 as Assessed by Magnetic Resonance Imaging (MRI) - Proton Density Fat Fraction (PDFF) — -10.94; -32.62; -41.14…
Phase 1 N=46 A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers
Tobacco Use Disorder
Primary: Assessment of Bioequivalence of Prototype Mini Lozenges With Nicorette Mini Lozenge by Measuring Area Under the Plasma Concentration Versus Time Curve From Time Zero to…
Phase 1 N=58 Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream
Photoallergy
Primary: Within-subject Comparison of Dermal Reaction by the Overall Numeric Rating of Erythema and Edema at 5 Defined Test Sites, After Application of MC2-01 Cream, MC2-01…
Phase 1 N=15 Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects
Intra-subject Variability of Pharmacokinetics
Primary: Cmax — 0.961; 2.34; 23.6; 1.02 ng/mL
Phase 1 N=42 Malaria: Relative Bioavailability and Food Effect of DSM265
Healthy Volunteers
Primary: Cmax — 15300; 14200; 11200 NG/ML — p=0.4847
Phase 1 N=79 Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Advanced Solid Tumors · Gastric Cancer · Transitional Cell Carcinoma of the Bladder
Primary: Number of Participants With Protocol Specified Dose-limiting Toxicities (Part 1 Only). — 0; 0; 0; 0 Participants